Biotech RadarJobs updated

COMPANY

NiKang Therapeutics

HQ: Wilmington, DE source · nikangtx.com ↗ · Mid-Atlantic

Clinical Phase 2

Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. Our research relies on disease biology insights and structure-based drug design with a current focus on HIF2α, CDK2 and KRAS. From company website Source · Oct 13, 2026

Keywords: structure biology kras Ovarian Cancer Ovarian Neoplasms Ovarian Carcinoma Metastatic Ovarian Carcinoma Endometrial Neoplasms Endometrial Diseases Metastatic Endometrial Cancer Triple Negative Breast Cancer Metastatic Endometrial Carcinoma Advanced Endometrial Carcinoma Advanced Ovarian Carcinoma Gastric Cancer Advanced Gastric Carcinoma Metastatic Gastric Cancer Metastatic Gastric Carcinoma Small Cell Lung Cancer Small Cell Lung Carcinoma Triple Negative Breast Neoplasms Platinum-resistant Ovarian Cancer Platinum-refractory Ovarian Carcinoma CCNE1 Amplification Hormone Receptor Negative Breast Carcinoma Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Progesterone-receptor-positive Breast Cancer ccRCC Clear Cell Renal Cell Carcinoma Kidney Cancer Kidney Neoplasms Renal Cancer Renal Neoplasms Recurrent Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Refractory Renal Cell Carcinoma Advanced Renal Cell Carcinoma Renal Cell Carcinoma HR+ Breast Cancer CCNE1 Amplified Advanced Solid Tumors

Location: Wilmington, DE · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors source ↗
  2. Trial start Phase 1: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors source ↗
  3. Trial start Phase 1: A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors source ↗
  4. Trial start Phase 2: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) source ↗
  5. Trial start Phase 1/Phase 2: A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT06586957A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1RecruitingSep 19, 20242029-01 (estimated)
NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1RecruitingMar 25, 2025Jul 31, 2027 (estimated)
NCT05119335A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaPhase 1/Phase 2TerminatedOct 26, 2021Aug 22, 2025 (actual)
NCT05935748Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)Phase 2TerminatedJul 28, 2023Jun 30, 2025 (actual)
NCT06264921A Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsPhase 1TerminatedFeb 23, 2024Apr 7, 2025 (actual)
Feedback